Reducing HSV-2 Morbidity and Mortality: Routine Serologic Screening Still Not the Best Answer. Pearlman MD. JAMA 2023;329:469-471.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pearlman MD. Reducing HSV-2 Morbidity and Mortality: Routine Serologic Screening Still Not the Best Answer. JAMA 2023;329:469-471.
PMID: 36786801